WuXi Biologics Valuation
| WXIBF Stock | USD 3.63 0.41 12.73% |
At this time, the company appears to be overvalued. WuXi Biologics maintains a prevalent Real Value of $3.24 per share. The last-minute price of the company is $3.63. Our model calculates the value of WuXi Biologics from examining the company fundamentals such as Profit Margin of 0.31 %, return on asset of 0.0551, and Current Valuation of 29.3 B as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that WuXi Biologics' price fluctuation is unstable at this time. Calculation of the real value of WuXi Biologics is based on 3 months time horizon. Increasing WuXi Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the WuXi pink sheet is determined by what a typical buyer is willing to pay for full or partial control of WuXi Biologics. Since WuXi Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of WuXi Pink Sheet. However, WuXi Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.63 | Real 3.24 | Hype 3.63 | Naive 3.73 |
The real value of WuXi Pink Sheet, also known as its intrinsic value, is the underlying worth of WuXi Biologics Company, which is reflected in its stock price. It is based on WuXi Biologics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of WuXi Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of WuXi Biologics helps investors to forecast how WuXi pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of WuXi Biologics more accurately as focusing exclusively on WuXi Biologics' fundamentals will not take into account other important factors: WuXi Biologics Total Value Analysis
WuXi Biologics is at this time forecasted to have takeover price of 29.3 B with market capitalization of 34.77 B, debt of 640.51 M, and cash on hands of 9.86 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the WuXi Biologics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
29.3 B | 34.77 B | 640.51 M | 9.86 B |
WuXi Biologics Investor Information
About 14.0% of the company outstanding shares are owned by insiders. The company has Price/Earnings To Growth (PEG) ratio of 0.8. WuXi Biologics had not issued any dividends in recent years. The entity had 3:1 split on the 10th of December 2020. Based on the key indicators related to WuXi Biologics' liquidity, profitability, solvency, and operating efficiency, WuXi Biologics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in August.WuXi Biologics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. WuXi Biologics has an asset utilization ratio of 23.37 percent. This implies that the Company is making $0.23 for each dollar of assets. An increasing asset utilization means that WuXi Biologics is more efficient with each dollar of assets it utilizes for everyday operations.WuXi Biologics Ownership Allocation
WuXi Biologics retains a total of 4.22 Billion outstanding shares. 30% of WuXi Biologics outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.WuXi Biologics Profitability Analysis
The company reported the revenue of 10.29 B. Net Income was 3.39 B with profit before overhead, payroll, taxes, and interest of 4.83 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates WuXi Biologics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in WuXi Biologics and how it compares across the competition.
About WuXi Biologics Valuation
The pink sheet valuation mechanism determines WuXi Biologics' current worth on a weekly basis. Our valuation model uses a comparative analysis of WuXi Biologics. We calculate exposure to WuXi Biologics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of WuXi Biologics's related companies.WuXi Biologics Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the Peoples Republic of China, North America, Europe, and internationally. The company was incorporated in 2014 and is headquartered in Wuxi, China. Wuxi Biologics is traded on OTC Exchange in the United States.
8 Steps to conduct WuXi Biologics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates WuXi Biologics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct WuXi Biologics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain WuXi Biologics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine WuXi Biologics' revenue streams: Identify WuXi Biologics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research WuXi Biologics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish WuXi Biologics' growth potential: Evaluate WuXi Biologics' management, business model, and growth potential.
- Determine WuXi Biologics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate WuXi Biologics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
WuXi Biologics Growth Indicators
Investing in growth stocks can be very risky. If the company such as WuXi Biologics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 4.2 B | |
| Quarterly Earnings Growth Y O Y | 0.381 | |
| Forward Price Earnings | 30.1205 | |
| Retained Earnings | 7.2 B |
Complementary Tools for WuXi Pink Sheet analysis
When running WuXi Biologics' price analysis, check to measure WuXi Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy WuXi Biologics is operating at the current time. Most of WuXi Biologics' value examination focuses on studying past and present price action to predict the probability of WuXi Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move WuXi Biologics' price. Additionally, you may evaluate how the addition of WuXi Biologics to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |